These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 19564418

  • 1. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L, Houghton PJ.
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [Abstract] [Full Text] [Related]

  • 2. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F.
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [Abstract] [Full Text] [Related]

  • 3. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK, Pizzo SV.
    PLoS One; 2012 Jan; 7(12):e51735. PubMed ID: 23272152
    [Abstract] [Full Text] [Related]

  • 4. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [Abstract] [Full Text] [Related]

  • 5. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH.
    J Biol Chem; 2007 Aug 31; 282(35):25604-12. PubMed ID: 17599906
    [Abstract] [Full Text] [Related]

  • 6. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
    Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM.
    J Immunol; 2008 Dec 01; 181(11):8088-95. PubMed ID: 19018001
    [Abstract] [Full Text] [Related]

  • 7. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP.
    Mol Cell Biol; 2011 Jun 01; 31(12):2484-98. PubMed ID: 21482669
    [Abstract] [Full Text] [Related]

  • 8. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
    Julien LA, Carriere A, Moreau J, Roux PP.
    Mol Cell Biol; 2010 Feb 01; 30(4):908-21. PubMed ID: 19995915
    [Abstract] [Full Text] [Related]

  • 9. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR).
    Agrawal P, Chen YT, Schilling B, Gibson BW, Hughes RE.
    J Biol Chem; 2012 Jun 15; 287(25):21164-75. PubMed ID: 22544753
    [Abstract] [Full Text] [Related]

  • 10. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X, Wang X, Xu T, Zhong S, Shen Z.
    Tumour Biol; 2015 Jul 15; 36(7):5273-81. PubMed ID: 25666752
    [Abstract] [Full Text] [Related]

  • 11. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
    Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ.
    Am J Physiol Cell Physiol; 2009 Jun 15; 296(6):C1258-70. PubMed ID: 19357233
    [Abstract] [Full Text] [Related]

  • 12. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J.
    PLoS One; 2015 Jun 15; 10(7):e0132880. PubMed ID: 26176608
    [Abstract] [Full Text] [Related]

  • 13. XPLN is an endogenous inhibitor of mTORC2.
    Khanna N, Fang Y, Yoon MS, Chen J.
    Proc Natl Acad Sci U S A; 2013 Oct 01; 110(40):15979-84. PubMed ID: 24043828
    [Abstract] [Full Text] [Related]

  • 14. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY.
    Oncotarget; 2015 Apr 20; 6(11):8974-87. PubMed ID: 25797247
    [Abstract] [Full Text] [Related]

  • 15. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY.
    Cancer Res; 2008 Sep 15; 68(18):7409-18. PubMed ID: 18794129
    [Abstract] [Full Text] [Related]

  • 16. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.
    Mol Cell Biol; 2009 Mar 15; 29(6):1411-20. PubMed ID: 19114562
    [Abstract] [Full Text] [Related]

  • 17. Raptor and Rheb negatively regulate skeletal myogenesis through suppression of insulin receptor substrate 1 (IRS1).
    Ge Y, Yoon MS, Chen J.
    J Biol Chem; 2011 Oct 14; 286(41):35675-35682. PubMed ID: 21852229
    [Abstract] [Full Text] [Related]

  • 18. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
    Luo Y, Liu L, Wu Y, Singh K, Su B, Zhang N, Liu X, Shen Y, Huang S.
    Oncotarget; 2015 Feb 28; 6(6):4286-98. PubMed ID: 25738366
    [Abstract] [Full Text] [Related]

  • 19. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.
    Toschi A, Lee E, Gadir N, Ohh M, Foster DA.
    J Biol Chem; 2008 Dec 12; 283(50):34495-9. PubMed ID: 18945681
    [Abstract] [Full Text] [Related]

  • 20. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
    Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM.
    Oncogene; 2008 Nov 27; 27(56):7106-17. PubMed ID: 18776922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.